Platelet Protein PF4 Reverses Aging in Blood Stem Cells

Blood production depends on hematopoietic stem cells (HSCs) residing in specialized bone marrow niches. With aging, HSCs accumulate damage, skew output toward myeloid lineages, lose regenerative power, and expand clonally — changes that predispose individuals to hematologic malignancies and immune decline. A key but poorly understood contributor to this process is the bone marrow megakaryocyte (MK) niche, which normally maintains HSC quiescence.

Using 3D whole-mount imaging and flow cytometry in young (2–3 month) and old (18–24 month) mice, the authors documented profound age-related MK niche remodeling: more numerous but smaller, less mature, lower-ploidy megakaryocytes that fail to restrain HSC expansion in vitro or in vivo. RNA sequencing of sorted MKs showed upregulation of inflammatory genes (IL-1b, IL-6, CCL3, CCL4) and downregulation of maturation-associated genes including Gata1 and Pf4. PF4 protein was also significantly lower in old mouse serum, consistent with published human plasma data showing age-dependent PF4 decline.

To isolate PF4's causal role, the team studied Pf4−/− mice, which are otherwise young and healthy. These animals recapitulated multiple hallmarks of physiological HSC aging: lymphopenia, elevated myeloid output, increased DNA damage accumulation, and impaired reconstitution in competitive transplantation assays. This strongly suggests PF4 loss is sufficient to accelerate HSC aging independent of other age-related changes.

Most therapeutically striking, systemic administration of recombinant PF4 to old mice reversed several aging phenotypes in HSCs: cell polarity (a hallmark of stemness) was restored, DNA damage markers decreased, in vivo reconstitution capacity improved, and lineage output rebalanced toward lymphoid production. The receptors mediating PF4's effect on HSCs were identified as LDLR (low-density lipoprotein receptor) and CXCR3 (a chemokine receptor). Mice doubly deficient in both receptors displayed exacerbated HSC aging phenotypes mirroring those of Pf4−/− animals, confirming functional relevance of this signaling axis.

Critically, human HSCs from donors across multiple age groups also responded to PF4 treatment in functional assays, suggesting conservation of this mechanism across species and its potential as a therapeutic target. These findings position PF4 as a niche-derived, age-sensitive factor whose decline contributes causally to HSC aging and whose restoration can partially reverse it, opening a path toward interventions for age-related blood diseases including clonal hematopoiesis and immunosenescence.